Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > This is why i love this board
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2261)
•••
Comment by Boomskidon Jan 23, 2023 11:02pm
83 Views
Post# 35241422

RE:RE:RE:RE:RE:RE:RE:This is why i love this board

RE:RE:RE:RE:RE:RE:RE:This is why i love this board Umm, Craigee Poo, let me explain. It was decided long ago that xB3 does not need to be tested against NHPs. Individual xB3-Payloads may need to be tested against NHPs but that's dependent almost solely on the payload.

Repeat after me in this order.

A) Test in small animals, mice, usually.
B) Submit to FDA or another drug agency for IND or equivalant approval.
C) Test in humans. These tests is called clinical trials.

Bioasis, I contend, has had nothing submitted for IND approval because of bad management. Even the FDA told Bioasis in its response to the xB3-001 pre-IND submission, yes, send it in for IND approval. We may even grant you fast-track status of some sort.

But of course, you and uncle know more these things than the FDA does.

Laffer...!!

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities